COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
SARS-CoV-2 may spread from individuals who are presymptomatic or asymptomatic, according to a new Centers for Disease Control and Prevention report based on epidemiologic, virologic and modeling studies before CDC recommended widespread use of face masks.
The CDC updated guidance designed to keep health care personnel safe during the COVID-19 pandemic, along with patient isolation strategies to ensure consistency in CDC’s criteria for patient discontinuation of transmission-based precautions and health care personnel return-to-work guidance.
The Centers for Disease Control and Prevention issued preliminary guidance for the development of forthcoming contact tracing apps that can help slow the spread of COVID-19.
The Food and Drug Administration said it is adopting more stringent standards for COVID-19 antibody tests.
The Food and Drug Administration issued Gilead Sciences an emergency use authorization for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
The Food and Drug Administration issued Gilead Sciences an emergency use authorization for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
The Food and Drug Administration issued Gilead Sciences an emergency use authorization for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
An independent commission will assess the response to COVID-19 and offer recommendations to nursing homes, the Centers for Medicare & Medicaid Services announced.
The Food and Drug Administration yesterday approved for emergency use a ventilator specially developed by the National Aeronautics and Space Administration to treat COVID-19 patients.
The Centers for Medicare & Medicaid Services released a number of new waivers related to COVID-19. The waivers apply nationwide and are generally retroactive to March 1, 2020.